Loss of RESponse to Ustekinumab Treated by Dose Escalation (REScUE)
Sponsor: Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW
Listed as NCT04245215, this PHASE3 trial focuses on Crohn Disease and remains completed. Sponsored by Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW, it has been updated 12 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Oct 2024 — Present [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Dec 2023 — Apr 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Jan 2023 — Dec 2023 [monthly]
Recruiting PHASE3
-
Mar 2022 — Jan 2023 [monthly]
Recruiting PHASE3
-
Sep 2021 — Mar 2022 [monthly]
Recruiting PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Apr 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Feb 2020 — Mar 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW
- Janssen Cilag N.V./S.A.
For direct contact, visit the study record on ClinicalTrials.gov .